Evolus Inc Stock Price To Sales

EOLS Stock

USD 13.25 0.22 1.63%

Evolus Inc fundamentals help investors to digest information that contributes to Evolus' financial success or failures. It also enables traders to predict the movement of Evolus Stock. The fundamental analysis module provides a way to measure Evolus' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Evolus stock.

		Last Reported	Projected for Next Year
	Price To Sales Ratio	2.59	4.30

Price To Sales Ratio is likely to gain to 4.30 in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Evolus Inc Company Price To Sales Analysis

Evolus' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

P/S

MV Per Share

Revenue Per Share

More About Price To Sales | All Equity Analysis

Current Evolus Price To Sales

3.22 X

Most of Evolus' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evolus Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Evolus Price To Sales Driver Correlations

Understanding the fundamental principles of building solid financial models for Evolus is extremely important. It helps to project a fair market value of Evolus Stock properly, considering its historical fundamentals such as Price To Sales. Since Evolus' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Evolus' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Evolus' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Good Will	Short Term Investments	Total Liab	Deferred Long Term Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Capital Surpluse	Net Receivables	Net Invested Capital	Net Working Capital	Long Term Debt	Capital Stock	Common Stock	Long Term Debt Total	Property Plant Equipment	Current Deferred Revenue
Total Assets		-0.65	0.29	-0.51	-0.79	0.81	-0.32	0.67	0.79	-0.94	0.56	1.0	-0.32	-0.46	0.88	-0.84	-0.2	0.9	0.78	-0.32	-0.32	-0.71	-0.68	0.6
Total Stockholder Equity	-0.65		-0.12	0.25	0.22	-0.46	-0.2	-0.05	-0.51	0.52	-0.26	-0.65	0.02	-0.11	-0.35	0.71	0.06	-0.44	-0.16	-0.2	-0.2	0.25	0.23	0.05
Net Tangible Assets	0.29	-0.12		-0.71	-0.14	0.04	-0.01	0.29	-0.33	-0.16	-0.31	0.3	-0.79	-0.1	0.22	-0.41	0.36	0.62	0.31	-0.01	-0.01	-0.02	-0.34	0.22
Net Debt	-0.51	0.25	-0.71		0.5	-0.47	0.49	-0.51	-0.04	0.36	0.23	-0.5	0.84	0.4	-0.41	0.53	0.1	-0.7	-0.46	0.49	0.49	0.5	0.51	-0.43
Retained Earnings	-0.79	0.22	-0.14	0.5		-0.84	0.57	-0.92	-0.74	0.77	-0.36	-0.79	0.47	0.86	-0.91	0.59	0.48	-0.76	-0.9	0.57	0.57	0.97	0.87	-0.91
Accounts Payable	0.81	-0.46	0.04	-0.47	-0.84		-0.33	0.65	0.76	-0.74	0.31	0.81	-0.38	-0.51	0.8	-0.72	-0.46	0.7	0.74	-0.33	-0.33	-0.82	-0.65	0.64
Good Will	-0.32	-0.2	-0.01	0.49	0.57	-0.33		-0.61	-0.31	0.32	-0.24	-0.3	0.26	0.71	-0.34	-0.01	0.26	-0.32	-0.46	1.0	1.0	0.63	0.44	-0.51
Short Term Investments	0.67	-0.05	0.29	-0.51	-0.92	0.65	-0.61		0.54	-0.66	0.35	0.68	-0.48	-0.93	0.87	-0.41	-0.28	0.72	0.84	-0.61	-0.61	-0.89	-0.95	0.95
Total Liab	0.79	-0.51	-0.33	-0.04	-0.74	0.76	-0.31	0.54		-0.83	0.73	0.79	0.14	-0.46	0.77	-0.56	-0.46	0.51	0.64	-0.31	-0.31	-0.73	-0.51	0.53
Deferred Long Term Liab	-0.94	0.52	-0.16	0.36	0.77	-0.74	0.32	-0.66	-0.83		-0.72	-0.94	0.19	0.51	-0.9	0.82	0.4	-0.85	-0.71	0.32	0.32	0.68	0.61	-0.58
Short Long Term Debt	0.56	-0.26	-0.31	0.23	-0.36	0.31	-0.24	0.35	0.73	-0.72		0.56	0.49	-0.27	0.57	-0.27	-0.17	0.33	0.31	-0.24	-0.24	-0.32	-0.27	0.27
Total Current Assets	1.0	-0.65	0.3	-0.5	-0.79	0.81	-0.3	0.68	0.79	-0.94	0.56		-0.32	-0.46	0.9	-0.85	-0.21	0.9	0.78	-0.3	-0.3	-0.71	-0.69	0.61
Short Term Debt	-0.32	0.02	-0.79	0.84	0.47	-0.38	0.26	-0.48	0.14	0.19	0.49	-0.32		0.4	-0.33	0.46	0.07	-0.63	-0.53	0.26	0.26	0.39	0.48	-0.47
Intangible Assets	-0.46	-0.11	-0.1	0.4	0.86	-0.51	0.71	-0.93	-0.46	0.51	-0.27	-0.46	0.4		-0.7	0.23	0.48	-0.5	-0.68	0.71	0.71	0.88	0.85	-0.87
Capital Surpluse	0.88	-0.35	0.22	-0.41	-0.91	0.8	-0.34	0.87	0.77	-0.9	0.57	0.9	-0.33	-0.7		-0.69	-0.34	0.85	0.85	-0.34	-0.34	-0.82	-0.85	0.85
Net Receivables	-0.84	0.71	-0.41	0.53	0.59	-0.72	-0.01	-0.41	-0.56	0.82	-0.27	-0.85	0.46	0.23	-0.69		0.36	-0.85	-0.55	-0.01	-0.01	0.49	0.45	-0.33
Net Invested Capital	-0.2	0.06	0.36	0.1	0.48	-0.46	0.26	-0.28	-0.46	0.4	-0.17	-0.21	0.07	0.48	-0.34	0.36		-0.15	-0.15	0.26	0.26	0.55	0.2	-0.28
Net Working Capital	0.9	-0.44	0.62	-0.7	-0.76	0.7	-0.32	0.72	0.51	-0.85	0.33	0.9	-0.63	-0.5	0.85	-0.85	-0.15		0.8	-0.32	-0.32	-0.63	-0.7	0.65
Long Term Debt	0.78	-0.16	0.31	-0.46	-0.9	0.74	-0.46	0.84	0.64	-0.71	0.31	0.78	-0.53	-0.68	0.85	-0.55	-0.15	0.8		-0.46	-0.46	-0.78	-0.78	0.87
Capital Stock	-0.32	-0.2	-0.01	0.49	0.57	-0.33	1.0	-0.61	-0.31	0.32	-0.24	-0.3	0.26	0.71	-0.34	-0.01	0.26	-0.32	-0.46		1.0	0.63	0.44	-0.51
Common Stock	-0.32	-0.2	-0.01	0.49	0.57	-0.33	1.0	-0.61	-0.31	0.32	-0.24	-0.3	0.26	0.71	-0.34	-0.01	0.26	-0.32	-0.46	1.0		0.63	0.44	-0.51
Long Term Debt Total	-0.71	0.25	-0.02	0.5	0.97	-0.82	0.63	-0.89	-0.73	0.68	-0.32	-0.71	0.39	0.88	-0.82	0.49	0.55	-0.63	-0.78	0.63	0.63		0.86	-0.85
Property Plant Equipment	-0.68	0.23	-0.34	0.51	0.87	-0.65	0.44	-0.95	-0.51	0.61	-0.27	-0.69	0.48	0.85	-0.85	0.45	0.2	-0.7	-0.78	0.44	0.44	0.86		-0.91
Current Deferred Revenue	0.6	0.05	0.22	-0.43	-0.91	0.64	-0.51	0.95	0.53	-0.58	0.27	0.61	-0.47	-0.87	0.85	-0.33	-0.28	0.65	0.87	-0.51	-0.51	-0.85	-0.91

Click cells to compare fundamentals

Evolus Price To Sales Historical Pattern

Today, most investors in Evolus Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Evolus' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Evolus price to sales as a starting point in their analysis.

Evolus Price To Sales

Timeline

The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Competition

Predict Evolus

Price To Sales Ratio Over Time

Evolus Price To Sales Ratio

Price To Sales Ratio

4.3

At this time, Evolus' Price To Sales Ratio is comparatively stable compared to the past year.

Based on the latest financial disclosure, Evolus Inc has a Price To Sales of 3.2167 times. This is 84.97% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The price to sales for all United States stocks is 71.83% higher than that of the company.

Evolus Price To Sales Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evolus' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Evolus could also be used in its relative valuation, which is a method of valuing Evolus by comparing valuation metrics of similar companies.

Evolus is currently under evaluation in price to sales category among its peers.

Evolus Current Valuation Drivers

We derive many important indicators used in calculating different scores of Evolus from analyzing Evolus' financial statements. These drivers represent accounts that assess Evolus' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Evolus' important valuation drivers and their relationship over time.

	2020	2021	2022	2023	2024	2025 (projected)
Market Cap	113.4M	324.0M	421.1M	599.4M	684.7M	718.9M
Enterprise Value	149.1M	252.5M	440.3M	663.1M	606.2M	636.5M

Evolus ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Evolus' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Evolus' managers, analysts, and investors.

Environmental

Governance

Social

Evolus Fundamentals

	Return On Equity	-8.62
	Return On Asset	-0.0808
	Profit Margin	(0.19) %
	Operating Margin	(0.01) %
	Current Valuation	887.46 M
	Shares Outstanding	63.59 M
	Shares Owned By Insiders	10.59 %
	Shares Owned By Institutions	82.62 %
	Number Of Shares Shorted	6.56 M
	Price To Earning	(5.55) X
	Price To Book	152.92 X
	Price To Sales	3.22 X
	Revenue	264.31 M
	Gross Profit	182.3 M
	EBITDA	(25 M)
	Net Income	(50.42 M)
	Cash And Equivalents	84.48 M
	Cash Per Share	1.51 X
	Total Debt	8.47 M
	Debt To Equity	1.59 %
	Current Ratio	2.60 X
	Book Value Per Share	0.09 X
	Cash Flow From Operations	(18 M)
	Short Ratio	9.05 X
	Earnings Per Share	(0.82) X
	Price To Earnings To Growth	(0.52) X
	Target Price	24.14
	Number Of Employees	332
	Beta	1.28
	Market Capitalization	856.51 M
	Total Asset	232.57 M
	Retained Earnings	(609.4 M)
	Working Capital	88.38 M
	Current Asset	27.24 M
	Current Liabilities	76.8 M
	Net Asset	232.57 M

About Evolus Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Evolus Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evolus using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evolus Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Evolus Stock Analysis

When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC